Recently, methionly-hGH was produced in the E. coli K-12, W3110 by recombinant DNA technology in Korea. In this paper, the clinical efficacy and immunogenicity of this GH were studied in 43 patients with growth hormone deficency.
The subjects of this study were aged 4.3~18.5 years and each patients received GH 0.5~0.7IU/kg/ week subcutaneously, 6~7 times a week for 1 year. During treatment, height, body weight and bone age were checked. Blood count, urinalysis. Blood
chemistry
and thyroid hormonal concentrations were checked before and every 3 months. The measurement of IGF-1 was performed and assay of antibody against hGH was performed before and every 6 months.
The height velocities significantly increased from 3.7±3.0cm/year to 11.0±4.2cm/year and 9.9±3.2cm/year at 6 and 12 months after GH therapy, respectively. The Height SDS were significantly improved after GH therapy with increasing ratio of
bone
age
to chronological age from 0.60±0.19 at pretreatment to 0.68±0.16 at 6 month. 0.69±0.16 at 12 month of therapy. The plasma IGF-1 levels significantly increased during treatment. Three out of 35 patients(8.3%) showed antibody against hGH after 1
year
of treatment. Thoughout study, we could not observe any remarkable side effect with GH treatment.
The results indicate that this E. coli derived methionly recombinant growth hormone is effective in improving the index of linear growth in the children with growth hormone deficiency without significant side effect(J Kor Soc Endocrinol
10:377~385,
1995).
|